View source for Medicine:John Theurer Cancer Center

{{Infobox hospital
| name = John Theurer Cancer Center
| location = 92 2nd Street, Hackensack, New Jersey
| country = US
| funding = Non-profit
| type = Cancer treatment
| affiliation = Hackensack University Medical Center

Georgetown Lombardi Comprehensive Cancer Center

Memorial Sloan Kettering Cancer Center
| network = Hackensack Meridian Health
}}'''John Theurer Cancer Center''' ('''JTCC''') at the Hackensack University Medical Center (HUMC), and part of the Hackensack Meridian Health (HMH), specializes in [[Medicine:Oncology|oncology]] services and treatments.<ref name=":2">{{Cite web |title=Hackensack Meridian John Theurer Cancer Center |url=https://www.hackensackmeridianhealth.org/en/Services/Cancer-Care |url-status=live |archive-url= |archive-date= |access-date=2022-03-26}}</ref> It is known for being the first site approved to use cell-based gene therapy to treat patients with certain types of large B-cell lymphoma who have not responded or relapsed after at least two other kinds of treatment; it initiated the first [[Biology:CAR T cell|CAR T-cell therapy]] clinical trials and is a member of the [[Organization:National Cancer Institute|NCI]]-approved Georgetown Lombardi Comprehensive Cancer Center. Other areas of concentration include bone marrow transplants, [[Biology:Stem cell|stem cell]] transplantation, [[Medicine:Lymphoma|lymphoma]], [[Medicine:Leukemia|leukemia]], [[Medicine:Multiple myeloma|multiple myeloma]], [[Biology:Neuro-oncology|neuro-oncology]], [[Biology:Skin|cutaneous]] malignancy, [[Biology:Gastrointestinal tract|gastrointestinal]], geriatric, head and neck, [[Biology:Thorax|thoracic]], urologic, breast, and [[Medicine:Gynaecology|gynecologic]].<ref>{{Cite web |title=Hackensack, NJ |url=https://www.regionalcancercare.org/locations/hackensack/ |access-date=2022-11-17 |website=Regional Cancer Care Associates |language=en-US}}</ref> As of 2023, Andre Goy is chair and Chief Physician Officer.<ref>{{Cite journal |last=Goy |first=Andre |date=2022-11-14 |title=Andre H. Goy, MD, on Unresolved Questions in Mantle Cell Lymphoma |url=https://www.cancernetwork.com/view/journal-andre-h-goy-md-on-unresolved-questions-in-mantle-cell-lymphoma |journal=Oncology |volume=36 |issue=11 |language=en |pages=651–653}}</ref><ref>{{Cite web |title=Dr Andre Goy on Predictive Biomarker Use for CAR T-Cell Therapy Response in Patients With Large B-Cell Lymphoma |url=https://www.ajmc.com/view/dr-andre-goy-on-predictive-biomarker-use-for-car-t-cell-therapy-response-in-patients-with-large-b-cell-lymphoma |access-date=2022-02-22 |website=AJMC |language=en}}</ref><ref>{{Cite web |title=Andre Goy, MD, Appointed Physician-in-Chief to Lead Cancer Care Across Hackensack Meridian Health Network |url=https://www.onclive.com/view/andre-goy-md-appointed-physician-in-chief-to-lead-cancer-care-across-hackensack-meridian-health |access-date=2023-04-11 |website=OncLive |language=en}}</ref>

== Georgetown Lombardi Comprehensive Cancer Center affiliation ==
In 2019, JTCC received approval from the [[Organization:National Cancer Institute|National Cancer Institute]] (NCI) as a member of the [[Organization:National Cancer Institute|NCI]]-approved Georgetown Lombardi Comprehensive Cancer Center.<ref>{{Cite web |date=2019-05-10 |title=NCI approves Georgetown-Hackensack consortium |url=https://cancerletter.com/the-cancer-letter/20190510_1/ |access-date=2021-08-27 |website=The Cancer Letter |language=en-US}}</ref> The partnership focuses on advancing research and treatment in [[Medicine:Breast cancer|breast cancer]], cancer prevention and control, experimental therapeutics and [[Chemistry:Molecular oncology|molecular oncology]].<ref>{{Cite web |last=Vecchione |first=Anthony |date=2019-05-07 |title=NCI approves John Theurer Cancer Center as research consortium member |url=https://njbiz.com/national-cancer-institute-approves-john-theurer-cancer-center-research-consortium-member/ |access-date=2021-08-27 |website=NJBIZ |language=en-US}}</ref><ref name=":02">{{Cite web |title=NCI Approves John Theurer Cancer Center as Member of Research Consortium - The ASCO Post |url=https://ascopost.com/issues/june-10-2019/nci-approves-john-theurer-cancer-center-as-member-of-research-consortium/ |access-date=2021-08-27 |website=ascopost.com}}</ref><ref>{{Cite web |last=Washburn |first=Lindy |title=New cancer treatment options in Passaic County from health system partnership |url=https://www.northjersey.com/story/news/health/2022/01/14/passaic-county-nj-hackensack-meridian-health-st-josephs-partnership-cancer-treatment/6516140001/ |access-date=2023-02-22 |website=North Jersey Media Group |language=en-US}}</ref> The Georgetown Lombardi Comprehensive Center is designated by the [[Organization:National Cancer Institute|National Cancer Institute]] as a leader in cancer treatment.<ref>{{Cite web |date=2012-07-26 |title=Georgetown Lombardi Comprehensive Cancer Center - NCI |url=https://www.cancer.gov/research/infrastructure/cancer-centers/find/georgetownlombardi |access-date=2023-03-22 |website=www.cancer.gov |language=en}}</ref>

== Hackensack University Medical Center and Hackensack Meridian Health affiliations ==
JTCC is part of Hackensack University Medical Center. HUMC and part of the Hackensack Meridian Health network, which includes Joseph M. Sanzari Children's Hospital, the ''Cancer Center,'' a branch of The Betty Torricelli Institute for Breast Care, Ocean Medical Center, Pascack Valley Medical Center, and the Riverview Medical Center.<ref name=":1">{{Cite web |title=Small numbers of cells in a tumor could be key enablers of cancer metastasis |url=https://www.eurekalert.org/news-releases/534933 |access-date=2022-02-22 |website=EurekAlert! |language=en}}</ref><ref>{{Cite web |title=St. Joseph’s Health and Hackensack Meridian Health: Affiliation Brings More Advanced Cancer Care To Northern New Jersey |url=https://www.tapinto.net/towns/paterson/sections/health-and-wellness/articles/st-joseph-s-health-and-hackensack-meridian-health-affiliation-brings-more-advanced-cancer-care-to-northern-new-jersey |access-date=2023-03-04 |website=TAPinto |language=en}}</ref><ref name="shorenewsnetwork.com">{{Cite web |last= |first= |date=2021-03-30 |title=Hackensack Meridian Health John Theurer Cancer Center (JTCC) creates affiliation with Regional Cancer Care Associates (RCCA) in Toms River, NJ |url=https://www.shorenewsnetwork.com/2021/03/30/hackensack-meridian-health-john-theurer-cancer-center-jtcc-creates-affiliation-with-regional-cancer-care-associates-rcca-in-toms-river-nj/ |access-date=2023-04-13 |website=Shore News Network |language=en-US}}</ref>

In 2022, JTCC expanded its program to Hackensack Meridian Jersey Shore University Medical Center's HOPE Tower, providing access to specialized cancer services and access to clinical trials.<ref>{{Cite web |last=Ebenau |first=Vin EbenauVin |title=Jersey Shore University Medical Center now has expansive cancer care center with easier access for Ocean and Monmouth residents |url=https://wobm.com/jersey-shore-university-medical-center-has-new-cancer-care-center/ |access-date=2023-04-11 |website=92.7 WOBM |language=en}}</ref>

==== Other affiliations ====
JTCC has a partnership with Memorial Sloan Kettering Cancer Center (MSK) to provide cancer care and develop joint standards of care through the oversight of a governing board composed of members from both MSK and HMH.<ref name=":3">{{Cite web |title=Memorial Sloan Kettering and Hackensack Meridian Health |url=https://msk-hmhpartnership.org |access-date=November 17, 2022 |website=Sloan Kettering}}</ref>

In 2021, JTCC entered into a clinical affiliation with Regional Cancer Care Associates (RCCA) to open a practice called Toms River Regional Cancer Center in Toms Rive<nowiki/>r, NJ. The center provides comprehensive medical and surgical oncology/hematology consultative services by community-based, regional, and national specialists for various types and stages of cancer and serious blood disorders.<ref name="shorenewsnetwork.com"/>

In 2022, JTCC entered into a [[Social:Clinical collaboration|clinical affiliation]] with St. Joseph's Health to provide expanded cancer care services to the residents of Wayne, Paterson, and Totowa.

== Green initiatives ==
In 2011, JTCC at HUMC opened a $130-million, 155,000-sq. ft. facility.<ref name=":2" /> The JTCC pavilion was built with a [[Biology:Green roof|green roof]], providing patients and visitors with a relaxing environment<ref>{{Cite web |title=Psychological Benefit of Green Roofs |url=https://www.ohio.edu/sites/default/files/sites/sustainability/files/Green%20Roof%20Psychosocial%20Benefits.pdf |access-date=March 21, 2023 |website=Ohio.edu}}</ref> and doubling as exterior insulation—greatly reducing heat gain and loss.<ref>{{Cite web |title=Does a green roof have an insulating effect? - Sempergreen |url=https://www.sempergreen.com/en/solutions/green-roofs/frequently-asked-questions-green-roof/green-roof-insulation |access-date=2023-03-21 |website=www.sempergreen.com}}</ref> This reduces energy use for heating and cooling as well as harmful emissions.<ref>{{Cite news |title=John Theurer Cancer Center at the Hackensack University Medical Center - Greenroofs.com |language=en-US |work=Greenroofs.com |url=http://www.greenroofs.com/projects/john-theurer-cancer-center-at-the-hackensack-university-medical-center/ |access-date=2022-11-17}}</ref>

== Notable accomplishments ==

* JTCC initiated the first CAR T-cell therapy clinical trials through its NCI collaboration and became the first certified center in New Jersey to offer this treatment, in which a patient's own immune cells ([[Biology:T cell|T-cells]]) are trained to fight cancer.<ref>{{Cite web |title=John Theurer Cancer Center Recognized by US News & World Report |url=https://njbmagazine.com/njb-news-now/john-theurer-cancer-center-recognized-by-us-news-world-report/ |access-date=2023-04-13 |website=New Jersey Business Magazine |language=en-US}}</ref>
* JTCC supports the Northeast's largest [[Biology:Hematopoietic stem cell transplantation|bone marrow transplant]] (BMT) program and, in 2014, performed 400 transplants.<ref name=":02"/>
* Treated first US patient with an investigatory drug for relapsed [[Medicine:Glioblastoma|glioblastoma]] and other [[Biology:Anaplasia|anaplastic]] gliomas.<ref>{{Cite web |last=Lindner |first=Linda |date=2022-03-29 |title=John Theurer Cancer Center treats 1st patient in U.S. with investigational drug for brain cancer |url=https://www.roi-nj.com/2022/03/29/healthcare/john-theurer-cancer-center-treats-1st-patient-in-u-s-with-investigational-drug-for-brain-cancer/ |access-date=2022-11-17 |website=ROI-NJ |language=en-US}}</ref><ref>{{Cite journal |last=Tiek |first=Deanna M. |last2=Erdogdu |first2=Beril |last3=Razaghi |first3=Roham |last4=Jin |first4=Lu |last5=Sadowski |first5=Norah |last6=Alamillo-Ferrer |first6=Carla |last7=Hogg |first7=J. Robert |last8=Haddad |first8=Bassem R. |last9=Drewry |first9=David H. |last10=Wells |first10=Carrow I. |last11=Pickett |first11=Julie E. |last12=Song |first12=Xiao |last13=Goenka |first13=Anshika |last14=Hu |first14=Bo |last15=Goldlust |first15=Samuel A. |date=2022-06-24 |title=Temozolomide-induced guanine mutations create exploitable vulnerabilities of guanine-rich DNA and RNA regions in drug-resistant gliomas |url=https://www.science.org/doi/10.1126/sciadv.abn3471 |journal=Science Advances |language=en |volume=8 |issue=25 |pages=eabn3471 |doi=10.1126/sciadv.abn3471 |issn=2375-2548 |pmc=9216507 |pmid=35731869}}</ref>
* First to use a [[Biology:Biomarker|biomarker]] surveillance program that screens patients who are at high-risk for developing pancreatic cancer.<ref>{{Cite web |last=NJBIZ |date=2022-04-28 |title=Hackensack UMC unveils new pancreatic cancer test |url=https://njbiz.com/hackensack-umc-unveils-new-pancreatic-cancer-test/ |access-date=2022-11-17 |website=NJBIZ |language=en-US}}</ref>
* Among the first of limited U.S. sites approved to offer [[Biology:Axicabtagene ciloleucel|Yescarta]] ([[Biology:Axicabtagene ciloleucel|axicabtagene ciloleucel]]), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded or relapsed after at least two other kinds of treatment.<ref>{{Cite web |title=John Theurer Cancer Center First NJ Site Certified to offer CAR-T Cell Cancer Therapy |url=https://www.onclive.com/view/john-theurer-cancer-center-first-nj-site-certified-to-offer-cart-cell-cancer-therapy |access-date=2022-11-17 |website=OncLive |language=en}}</ref> As of 2023, it is also approved for all six commercially available CAR-T products for lymphoma, [[Medicine:Multiple myeloma|multiple myeloma]] and pediatric B-Cell precursor [[Medicine:Acute lymphoblastic leukemia|acute lymphoblastic leukemia]]: Yescarta, Tecartus ([[Biology:Brexucabtagene autoleucel|brexucabtagene autoleucel]]), Breyanzi ([[Biology:Lisocabtagene maraleucel|lisocabtagene maraleucel]]), Carvykti ([[Biology:Ciltacabtagene autoleucel|ciltacabtagene autoleucel]]), Abecma ([[Biology:Idecabtagene vicleucel|idecabtagene vicleucel]]), and Kymriah ([[Biology:Tisagenlecleucel|tisagenlecleucel]]).

== References ==
<references />

== External links ==

* [https://www.onclive.com/sap-partner/cancer-centers/jtcc OncLive]


{{DEFAULTSORT:John Theurer Cancer Center}}
[[Category:Cancer research]]

{{Sourceattribution|John Theurer Cancer Center|1}}